Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

4171 - Expression of androgen receptors in primary breast cancer


10 Oct 2016


Poster display


Amr Ghannam


Annals of Oncology (2016) 27 (6): 43-67. 10.1093/annonc/mdw364


A. Ghannam1, S. Galal2, M. Ellity2

Author affiliations

  • 1 Clinical Oncology Department, Tanta University-Faculty Of Medicine, 37 - Tanta/EG
  • 2 Pathology, Tanta University Hospital, 31111 - Tanta/EG


Abstract 4171


The objective of the study was to evaluate the prognostic effect of androgen receptor (AR) in breast cancers.


We investigated immunohistochemical AR expression from paraffin blocks of one hundred patients between 2007 and 2011, and analyzed demographics and outcomes using univariet analyses. Tumors with ≥10% nuclear-stained cells were considered positive for AR.


AR was expressed in 62% of patients. AR was significantly related to older age at diagnosis, smaller tumor size, histological type, higher positivity of hormone receptors and the administration of systemic treatment. In estrogen receptor (ER)-negative tumors, AR was distinctively associated with histological type and progesterone receptors unexpression. With a mean follow-up of 35.72 months, AR expression was a significant prognostic factor for DFS and OS in all patients. The 3-year DFS and OS of patients with AR-positive tumor were 87.1% and 90.73%, respectively. The 3-year DFS and OS of those with AR-negative tumor were 66.32% and 84.21%, respectively. AR expression was positively associated with survival outcomes in all patients.


AR is significantly associated with favorable features in breast cancers and related to better outcomes in ER-positive not in ER-negative tumors. These results suggest that AR could be an additional marker for endocrine responsiveness in ER-positive tumors and a candidate for therapeutic targeting of ER-negative tumors.

Clinical trial identification


Legal entity responsible for the study

Tanta University


Tanta Facultiy of Medicine


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings